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Abstract
Introduction—Heart failure (HF) and atrial fibrillation (AF) have been associated with a higher 
risk of Alzheimer’s disease (AD). Whether HF and AF are related to AD by enhancing AD 
neuropathological changes is unknown.
Methods—We applied network analyses and multiple logistic regression models to assess the 
association between HF and AF with severity of AD neuropathology in patients from the National 
Alzheimer’s Coordinating Center database with primary neuropathological diagnosis of AD.
Results—We included 1593 patients, of whom 129 had HF and 250 had AF. HF and AF patients 
were older and had milder AD pathology. In the network analyses, HF and AF were associated 
with milder AD neuropathology. In the regression analyses, age (odds ratio [OR] 0.94, 95% 
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confidence interval [CI] 0.93–0.95 per 1-year increase in age, P <.001) and the interaction term HF 
× AF (OR 0.61, 95% CI 0.40–0.91, P = .014) were inversely related to severe AD pathology, 
whereas APOE ε4 genotype showed a direct association (OR 1.68, 95% CI 1.31–2.16). Vascular 
neuropathology was more frequent in patient with HF and AF patients than in those without.
Discussion—HF and AF had milder AD neuropathology. Patients with milder AD lived longer 
and had more exposure to vascular risk factors. HF and AF patients showed a higher frequency of 
vascular neuropathology, which could have contributed to lower the threshold for clinically 
evident dementia.
Keywords
Atrial fibrillation; Heart failure; Dementia; Alzheimer’s disease; Vascular dementia; 
Neuropathology
1. Introduction
Heart failure (HF), atrial fibrillation (AF), and dementia are major health care challenges 
that become more prevalent with age [1–3]. The number of people over 65 years will 
increase from 420 million in 2000 to 1 billion by 2030 [4]. Therefore, this segment will 
grow from 7% to 12% of the population [4]. In consequence, the number of individuals 
living with dementia is predicted to escalate from 35.6 million in 2010, to 65.7 million in 
2030, and 115.4 million in 2050 [1]. Similarly, the prevalence of AF in the US population is 
expected to increase from 5.2 million in 2010 to 12.2 million in 2030 [2].
HF and AF constitute promising targets for dementia prevention. Evidence suggests that HF 
and AF are associated to a higher risk of cognitive impairment and dementia, irrespective of 
stroke history [5,6]. Whereas data from population-based studies show that HF is associated 
with a higher risk of Alzheimer’s disease (AD) [7,8], AF is not associated equally with all 
types of dementias [6]. Although there is evidence supporting the association between AF 
and dementia secondary to cerebrovascular disease, the relationship between AF and AD is 
still controversial [6]. One study that examined neuropathological changes associated with 
AF found that patients with permanent AF were 40%–50% more likely to have AD changes 
than those without AF, but these associations were not statistically significant [9].
Whether the higher AD risk of HF and AF is mediated through a greater burden of AD 
pathological changes is unknown. Several possible mechanisms may enhance AD-related 
pathological processes in HF and AF patients. Amyloid β clearance may be compromised in 
HF patients, whereas stroke-free AF patients have reduced hippocampal volume compared 
with matched subjects without AF, meaning that AF could be implicated in direct or indirect 
neurodegenerative processes [10,11]. Also, AF-related brain infarcts may potentiate AD 
pathological changes through secondary mechanisms [12].
In the present study, we aimed to investigate whether there is an association between HF and 
AF with severe AD neuropathology among cases with primary diagnosis of AD from the 
National Alzheimer’s Coordinating Center (NACC) database.
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2. Methods
The NACC was established by the National Institute on Aging in 1999 with the aim of 
enabling collaborative research (U01 AG016976). The NACC collects data from 34 past and 
present National Institute of Aging–funded Alzheimer’s disease Centers across the USA. 
For this study, neuropathological data were collected from the NACC Neuropathology Data 
Set, and clinical data from the same cases were obtained from the NACC Uniform Data Sets 
[13–15]. The Uniform Data Set has gathered information about demographic data, clinical 
manifestations, clinical diagnoses, neurological examination, functional status, 
neuropsychological assessment, genetic data, and neuropathological diagnoses since 2005.
For most of the neuropathological diagnoses, two categories were available: primary or 
contributing. For the purpose of this study, we selected cases with primary AD diagnosis. 
Cases received an AD neuropathological diagnosis based on Braak staging [16] and 
Consortium to Establish a Registry for Alzheimer’s Disease scores for likelihood of AD [17] 
if cases reached an intermediate probability. As such, the study cohort comprised patients 
with primary neuropathological diagnosis of AD without contributing cerebrovascular 
disease or with a degree of vascular neuropathology that did not reach the threshold for 
mixed dementia. This was possible because NACC includes two categories for vascular 
neuropathology (1) CVD (cerebrovascular disease), in which vascular neuropathology was 
classified as a primary or contributing neuropathology (Items 20E1-20E2 in Neuropathology 
Data Set) and (2) VP (vascular pathology) (Item 12), in which vascular neuropathology was 
recorded but did not reach a threshold deemed sufficient to contribute to clinical status. 
Cases in which AD was only contributing and not the primary neuropathological diagnosis 
were excluded. We decided to restrict the study population to patients with primary AD 
diagnosis because we wanted to test the hypothesis of whether HF and AF are implicated in 
pathophysiological mechanisms of AD degeneration. This would have been impracticable if 
we used a cohort comprising patients with mixed dementia in which secondary AD only 
represented a contributing secondary pathological mechanism.
We recorded data regarding sex, age at the onset of cognitive decline, age at the last visit, 
age at death, years of education, history of hypertension, AF, diabetes mellitus, 
hyperlipidemia, smoking (more than 100 cigarettes smoked in a lifetime), stroke, transient 
ischemic attack (TIA), and HF. These variables were coded as absent, recent/active, or 
remote/inactive. We merged active and inactive categories and compared them with the 
“absent” category. For the purpose of this study, patients were considered to have AF and 
HF based on their medical history (in any of all the available Uniform Data Set visits, form 
A5). We defined four clinical phenotypes (CPs) according to the presence or absence of HF 
and AF—(1) CP1: no HF and no AF, (2) CP2: AF without HF, (3) CP3: HF without AF, and 
(4) CP4: HF and AF present. History of stroke was defined by the presence of an affirmative 
response in any of the following three variables comprised in the original data set: stroke, 
history of stroke, and temporal relationship between stroke and onset of cognitive 
impairment.
We used Braak stages (extent of neurofibrillary tangles) to classify the severity of AD-
related neuropathological findings into severe (stages V/VI) and milder (stages III/IV) [16]. 
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Neuropathological vascular features comprised microinfarcts, lacunar macroscopic infarcts 
(lacunes), and larger macroscopic infarcts. The criteria used by the neuropathologists to 
assess the vascular features are described in the Neuropathology Diagnosis Coding 
Guidebook (https://www.alz.washington.edu/NONMEMBER/NP/npguide9.pdf). We defined 
four neuropathological profiles (NPs) on the basis of AD and vascular neuropathology—(1) 
NP1: Braak III/IV + vascular neuropathology, (2) NP2: Braak III/IV without vascular 
neuropathology, (3) NP3: Braak V/VI + vascular neuropathology, and (4) NP4: Braak V/VI 
without vascular neuropathology.
We used the NACC neuropsychological battery to assess cognitive status in the last visit 
before death [15]. The battery comprised the following domains and tests—(1) general 
cognitive impairment: Mini-Mental State Examination [18]; (2) executive functions: Digit 
Span Backward (Wechsler Memory Scale—Revised) [19], Digit Symbol Coding (Wechsler 
Adult Intelligence Scale—Revised) [20], and Trail Making Test, Part B [21]; (3) memory: 
immediate and delayed recall (Story A, Wechsler Memory Scale—Revised) [19]; (4) 
language: animal and vegetable list generation (verbal fluency) [22] and Boston Naming 
Test (naming) [23]; (5) attention: Digit Span Forward (Wechsler Memory Scale—Revised) 
[18] and Trail Making Test, Part A [20–24]. The dementia-related functional status was 
assessed according to the Clinical Dementia Rating (CDR) sum of boxes [25].
2.1. Statistical analysis
We performed univariate analyses to compare demographic characteristics, vascular risk 
factors, vascular comorbidities, and neuropathological findings between patients with and 
without AF and HF. The c2 to compare proportions and one-way analysis of variance to 
compare means across the four CPs. All tests were two tailed, and a P value <.05 was 
deemed statistically significant. We developed a forward step-by-step multiple logistic 
regression model to test whether AF and HF were associated with severe AD pathology 
(Braak stages V/VI). This model was adjusted for demographic data (e.g., age and sex), risk 
factors (e.g., hypertension, hyperlipidemia, smoking, and diabetes mellitus), and history of 
stroke/TIA. Measures of association were expressed as odds ratios (ORs) and 95% 
confidence intervals (CIs). We estimated the proportion of severe AD pathological findings 
(e.g., Braak stages V/VI), vascular neuropathology (e.g., microinfarcts, lacunes, or larger 
infarcts), and the frequency or each of the four prespecified NPs based on AD findings and 
vascular neuropathology across the four prespecified clinical HF/AF phenotypes. We used 
IBM SPSS Statistics 20.0 for Macintosh (IBM Corp.) for all statistical analyses.
As a post hoc analysis based on preliminary results of this study, we developed logistic 
regression analyses to identify predictors of early death. For this purpose, we used the lowest 
quintile of age at death (<72 years) as the dependent variable.
2.2. Network analysis
We built a network by relating demographic variables, risk factors, comorbidities, and 
pathological findings. We divided the data set into training and validation sets. The links 
between these variables, or nodes, were calculated by using relative risk as the correlation 
measure. We retained only relative risks that where above a certain threshold, which was 
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defined on the basis of the limit at which the giant component was first detected [26]. We 
identified connections that were stronger among patients with HF and AF than among 
patients without. We performed a modularity analysis based on the concept of topological 
overlap (analysis of the structure of the density and pattern of connections of the nodes 
within the network) to determine how variables were connected between each other [27]. For 
the network analyses, we were unable to use continuous variables; thus, we dichotomized 
age into <82 and 82 years on the basis of the median age of the cohort at death.
3. Results
The study cohort comprised 1593 patients with primary diagnosis of AD (Fig. 1). A total of 
129 patients had HF (8.1%) and 250 had AF (15.7%). Comparisons of demographic data, 
vascular risk factors, comorbidities, clinical diagnoses, and neuropathological findings 
across the four CPs are shown in Table 1. AD patients with HF and AF were older at the 
time of onset of cognitive decline and at death, had less frequent severe AD changes on 
neuropathological examination, and had more frequent noncontributory vascular 
neuropathology than those without HF or AF. Clinically, patients with HF and AF were 
more frequently considered as having normal cognition and were more often diagnosed as 
having dementia because of cerebrovascular disease than those without. Hypertension and 
all vascular comorbidities were more common in HF and AF patients than in those without. 
In general, cognitive performance and overall functional status (CDR) were better in patients 
with HF + AF than in those without (Table 2).
In the logistic regression model for severe AD changes, age (OR 0.94, 95% CI 0.93–0.95 per 
1-year increase in age, P < .001) and the interaction term HF × AF (OR 0.61, 95% CI 0.40–
0.91, P = .014) were inversely related to severe AD pathology, whereas APOE ε4 genotype 
showed a direct association (OR 1.68, 95% CI 1.31–2.16). Adding the interaction term 
APOE ε4 × HF × AF did not significantly affect these results.
We used a threshold of 1.20 for the network analyses (Fig. 1). The giant component 
comprised all vascular findings on neuropathological examination. The modularity analysis 
showed that the network had a high density of connections between HF, AF, vascular risk 
factors, and stroke, which belonged to the same module. HF and AF were only connected 
with milder AD neuropathological findings, and there was lack of connection with Braak 
stages V/VI. Conversely, HF and AF were highly connected to vascular neuropathology.
The frequency of severe AD pathology significantly decreased across clinical AF/HF 
phenotypes CP1 to CP4 (Fig. 2, panel A). Likewise, there were increasing proportions of 
vascular neuropathology across the same groups (Fig. 2, panel B). As shown in Fig. 3, the 
NPs AF and HF showed less severe AD pathology and more vascular neuropathology; and 
the combination of HF and AF had an additive effect resulting in even less frequent severe 
AD changes and more frequent vascular neuropathology.
HF (OR 0.29, 95% CI 0.09–0.94), AF (OR 0.22, 95% CI 0.11–0.45), and Braak stages V/VI 
(OR 3.07, 95% CI 1.87–5.04) were significantly associated with early death in the post hoc 
logistic regression model (Fig. 2).
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4. Discussion
Evidence suggests that stroke risk factors such as midlife hypertension and obesity, diabetes, 
smoking, and physical inactivity and comorbidities such as HF and AF are independently 
associated with an increased risk of AD and vascular cognitive impairment [6–8,28]. 
Contrary to our hypothesis, in the present study of cases from the NACC database with 
primary diagnosis of AD, we found that patients with HF and AF had less frequent severe 
AD changes on neuropathological examination than those without.
In the logistic regression models for severe AD pathology, the odds of showing severe AD 
pathology decreased by 5% per 1-year increase in age at death and 39% for patients who had 
both HF and AF. The network analyses showed an association between HF and AF with 
milder AD neuropathology. Together, these findings suggest that HF and AF occur more 
frequently in patients with milder AD pathology, who because of a more benign AD course 
may present with cognitive decline at older ages, live longer, and are more exposed to 
vascular risk factors leading to a higher prevalence of cardiovascular comorbidities [29]. 
This is further reinforced by the fact that severe AD pathology increased 3-fold the risk of 
early death in the study cohort and also by the finding of younger age of onset of cognitive 
decline among AD patients without HF or AF [2,30].
Another potential explanation for our findings is that HF and AF precede dementia 
symptoms and lead to overt dementia not by enhancing AD pathology, but rather by a higher 
prevalence of vascular neuropathology. Subjects with milder AD pathology would be 
clinically diagnosed with AD only in the presence of enough vascular neuropathology to 
lower the threshold for cognitive impairment [31], As such, the higher frequency of AD 
diagnosis among HF and AF patients found in prior studies may be explained by 
symptomatic and asymptomatic brain infarcts uncovering mild forms of AD [5,6]. 
Interestingly, the severity of vascular neuropathology in this cohort was a priori regarded as 
nonsignificant enough to clinically influence on cognitive performance by expert NACC 
neuropathologists. Indeed, HF and AF showed an additive effect in the proportion of patients 
with milder AD changes and greater vascular neuropathology. Also, AD patients with HF 
and AF had slightly better age- and sex-adjusted cognitive performances and overall 
functional status as those without, further supporting the idea that apparently nonclinically 
relevant vascular neuropathology may have lowered the threshold for cognitive impairment 
in older HF and AF patients who had milder AD neuropathology [31].
Our findings suggest that the apparent association between HF and AF with higher risk of 
AD is unlikely mediated through the enhancement of primary AD-related mechanisms. The 
higher proportion of primary AD with apparently, but not so, noncontributing vascular 
neuropathology among HF and AF patients and the additive effect of HF and AF on the 
frequency of vascular neuropathology suggest that brain infarcts otherwise regarded as 
nonclinically contributory to the diagnosis of dementia by expert pathologists could still play 
a role in secondary pathophysiological AD processes. Indeed, brain infarcts can lead to 
remote localized cortical thinning through degeneration of connecting fiber tracts, on top of 
the primary structural brain damage produced by ischemia itself [32]. Experimental and 
preliminary clinical data suggest that pre-existing amyloid may stimulate secondary cortical 
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neurodegenerative processes after acute stroke [7]. Chronic stroke-related inflammation is 
also involved in secondary neurodegenerative processes and seems to be independent of 
prior amyloid deposition [12]. However, all these findings need to be further validated.
This study has limitations. First, information about the presence of HF and AF was not 
systematically investigated and came from the subjects’ medical history as recorded 
retrospectively during their follow-up visits. This might have resulted in the underdiagnosis 
of the both conditions. However, it also reflects how history of HF and AF is usually 
investigated in routine clinical practice. Also, based on the large sample size, the finding of 
less severe AD pathology in patients who had HF or AF seems unlikely to be because of 
chance. This is further reinforced by the adjustment for significant confounders in the 
logistic regression models. Second, the retrospective ascertainment of HF and AF hinders 
the identification of the time sequence in the association between HF/AF and dementia. 
Third, we did not have information regarding the localization of brain infarcts, which would 
have likely enriched the analysis. Fourth, information about prescribed oral anticoagulants, 
antiplatelet agents, and other drugs were not available in the NACC data set. This precluded 
us from adjusting the regression models for drugs that have the potential to reduce the 
incidence of dementia or to delay its diagnosis. Despite this, the role of antithrombotic 
agents in dementia prevention is unknown. Fifth, our results are not generalizable to all 
types of dementia. The study cohort was designed to test the study hypothesis among 
patients with primary diagnosis of AD and not other dementias. Although this is a highly 
selected population, it still constitutes the most frequent type of dementia, and the results of 
this study are relevant to explain how HF and AF help to lower the threshold of cognitive 
impairment in patients with mild AD neurodegenerative changes.
Our study suggests that subjects with milder AD pathology live longer. Hence, they are 
exposed to a greater burden of vascular risk factors and have higher odds of developing HF 
and AF. As a result, rather than being considered as possible causes of AD, HF and AF may 
be possibly regarded as markers of milder AD pathology, lowering the threshold for the 
detection of cognitive impairment in subjects with milder AD pathology because of a higher 
presence of vascular neuropathology. In other words, HF and AF seem to contribute to the 
clinical expression of dementia in individuals with milder forms of AD, who would 
otherwise be able to function within cognitively acceptable limits. Strategies implemented 
during early adulthood to prevent HF and AF, and to effectively manage both conditions 
early after their diagnoses, may help delay the clinical expression of dementia among 
patients with milder forms of AD.
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RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the literature using traditional (e.g., 
PubMed and Scopus) sources. Relevant citations are cited throughout the text. 
Evidence suggests that heart failure (HF) and atrial fibrillation (AF) are 
associated with a higher risk of cognitive impairment and dementia, including 
Alzheimer’s disease (AD), irrespective of stroke history. The mechanisms 
behind these associations are still unknown.
2. Interpretation: Our findings suggest that HF and HD may be markers of 
milder AD pathology. Both HF and AF may contribute to a higher apparent 
dementia incidence by making milder forms of otherwise sub-clinical AD 
become clinically evident because of more frequent coexisting vascular 
neuropathology.
3. Future directions: Further studies should investigate the temporal association 
between HF, AF, and AD and whether clinically overt AD can be delayed or 
prevented by avoiding HF and AF and/or by optimizing their treatment.
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Fig. 1. 
Network analyses for neuropathological Alzheimer’s disease (AD) findings. Each variable is 
shown in a circle (node). Risk factors are shown in dark green, heart failure (HF) and atrial 
fibrillation (AF) in light green, stroke in black, vascular neuropathological findings in gray 
(borders in dotted lines), and Braak stages in red. The lines between circles are present only 
when the degree of association between the connected variables is higher than the 
prespecified threshold of 1.2. HF and AF are connected with milder AD pathology (Braak 
stages III/IV). They are also highly connected with age, diabetes, hypertension, stroke, and 
vascular neuropathology.
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Fig. 2. 
Frequency of severe Alzheimer’s disease (AD) pathological findings and vascular 
neuropathology in patients with and without atrial fibrillation (AF) and heart failure (HF). 
Panel A shows the proportion of severe AD pathological findings (e.g., Braak V/VI) on 
neuropathological examination for patients (i) without AF or HF, (ii) with AF, (iii) with HF, 
and (iv) with AF + HF. Panel B shows the proportion of vascular neuropathology for the 
same groups. Circles represent the proportion with neuropathological findings, and vertical 
lines account for the 95% confidence intervals.
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Fig. 3. 
Frequency of neuropathological profiles (NPs) of Alzheimer’s disease (AD) and vascular 
neuropathology in patients with and without atrial fibrillation (AF) and heart failure (HF). 
The figure shows the proportion of four prespecified NPs of AD findings and vascular 
neuropathology (e.g., Braak III/IV + vascular neuropathology, Braak III/IV without vascular 
neuropathology, Braak V/VI + vascular neuropathology, and Braak V/VI without vascular 
neuropathology) for patients (i) without AF or HF, (ii) with AF, (iii) with HF, and (iv) with 
AF + HF. VNP: vascular neuropathology (e.g., larger infarcts, lacunes, or microinfarcts).
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